Omeros (OMER) Insider Thomas Cable Buys 15,000 Shares

Thomas Cable purchased 15,000 shares of Omeros Corporation (OMER) on June 18, 2026, according to a recent filing with the SEC. This transaction was not part of a pre-arranged Rule 10b5-1 trading plan, which is a tool insiders sometimes use to schedule trades in advance to avoid conflicts of interest. Instead, the purchase appears to be a direct acquisition that coincided with a significant cluster of buying activity across the company's leadership team.

A Coordinated Wave of Insider Buying

The purchase by Cable was just one piece of a broader show of support from Omeros insiders. On the same day, June 18, 2026, six other individuals associated with the company also bought exactly 15,000 shares each. This group included Peter Demopulos, Arnold Hanish, Thomas Bumol, Rajiv Shah, Diana Perkinson, and Leroy Hood. This level of synchronized buying often suggests a shared confidence among those closest to the company's internal developments, particularly as Omeros continues to advance its clinical pipeline.

Omeros Stock and Market Position

Shares of Omeros were trading at $10.28 on Monday. The stock has seen a wide range of movement over the past year, hitting a high of $21.24 and a low of $6.24. At its current price, the company has a market value of roughly $1.36 billion. The stock is currently trading below its 50-day moving average of $18.23 but remains above its 200-day moving average of $13.34. With a price-to-earnings (P/E) ratio of 15.4, the company is priced similarly to many of its peers in the biotechnology sector that have reached profitability.

Recent Earnings and Financial Health

Omeros Corporation most recently reported annual revenue of $38.42 million. The company has managed to stay profitable with a net margin of 3.25% and earnings per share of $1.22. These figures are important for a clinical-stage biotech firm, as many companies in this space operate at a loss for years while developing new drugs. Investors are looking ahead to November 12, 2026, when Omeros is expected to release its next set of financial results.

Analysts Set New Price Targets

Wall Street analysts have maintained a generally positive view of Omeros. On October 14, 2026, Cantor Fitzgerald reiterated its Overweight rating on the stock with a $22.00 price target. This followed an upgrade by the same firm in September. Earlier, on June 26, 2026, H.C. Wainwright & Co. maintained a Buy rating, though it lowered its price target from $40.00 to $33.00. Currently, the two analysts covering the stock provide a consensus buy recommendation with an average price target of $27.50, suggesting they believe the shares could more than double from recent prices.

About Omeros Corporation

Omeros is a Seattle-based biotechnology company that creates protein and small-molecule therapies. Its work focuses on immunologic diseases and orphan indications, which are rare conditions that often lack dedicated treatments. The company's lead candidate, Narsoplimab, is being studied for complications related to stem-cell transplants and has also been tested for its effectiveness in treating severe respiratory issues. The recent cluster of insider buying highlights the high stakes as these clinical trials move forward.

What's Ahead for Omeros Corporation

The heavy buying by Thomas Cable and his colleagues provides a data point for investors to consider alongside the company's upcoming earnings report in November. While insider purchases can signal internal optimism, they are backward-looking disclosures and do not guarantee future stock performance. Market participants will likely watch for further updates on the company's clinical trials to see if the optimism shown by the board translates into regulatory progress.